Dr. John Minna, Core Co-Director and SPORE principal investigator and Dr. Jack Roth, Core Director and Co-Principal Investigator of the SPORE will provide the administrative leadership for Core A. They will facilitate the interactions of the project and core leaders and direct their SPORE activities to accomplish the following aims: 1. To direct the overall scientific quality of the SPORE and ensure communication, cooperation, and integration between The University of Texas Southwestern (UTSW) and The University of Texas MD Anderson Cancer Center (UTMDACC). 2. To monitor the overall compliance of the SPORE in conjunction with all general Governmental and specific NCI regulations and requirements. 3. Communicate and confer with the NCI Project Officer and other staff, and ensure all necessary reporting requirements. 4. Coordinate data quality control and quality assurance issues in conjunction with the Internal Review and Monitoring Committees of UTSW and MDACC and the Biostatistics and Bioinformatics (Core C). 5. Oversee expenditures and maintain budget information. 6. Organize all necessary meetings, including the Executive Committee, External and Internal Advisory Committees, monthly scientific videoconference meetings, lectures, symposia, and attendance at the Lung Cancer SPORE meetings. 7. Oversee the Developmental Research and Career Development Programs including obtaining mentors, biostatistical, and bioinformatics support and assist in selection of projects for funding. Specifically establish and monitor policies for recruitment of women and minorities to this program. 8. Coordinate and maintain Institutional commitment to the SPORE at UTSW and MDACC. 9. Encourage and facilitate inter SPORE communication, collaborations, cooperation, data and resource sharing. 10. Coordinate and facilitate SPORE interactions with the PHARMA and Biotech industry 11. Coordinate and facilitate Patient Advocate involvement in the SPORE.

Public Health Relevance

The SPORE Administrative Core provides scientific and administrative oversight for all of the SPORE Projects and Cores and the Developmental and Career Development Program. It also provides the main interface with the NCI, other Lung Cancer SPOREs, and other collaborating institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA070907-16A1
Application #
8747052
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
1996-09-30
Project End
2019-08-31
Budget Start
2014-09-23
Budget End
2015-08-31
Support Year
16
Fiscal Year
2014
Total Cost
$173,223
Indirect Cost
$34,710
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49
Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835
Zhou, Xiaorong; Padanad, Mahesh S; Evers, Bret M et al. (2018) Modulation of Mutant KrasG12D -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function. Mol Cancer Res :
Ferdosi, Shadi; Rehder, Douglas S; Maranian, Paul et al. (2018) Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, ?1-4 Branching, ?1-6 Branching, and ?2-6 Sialylation in Cancer. J Proteome Res 17:543-558
Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M et al. (2018) Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36:2386-2394
Abrams, Zachary B; Zucker, Mark; Wang, Min et al. (2018) Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics 19:738

Showing the most recent 10 out of 1059 publications